You are here

Th17 Inflammatory Pathway Therapeutics Markets, 2022

DUBLIN, July 26, 2019 /PRNewswire/ -- The "Th17 Inflammatory Pathway Therapeutics Report" report has been added to's offering.

Immune-mediated inflammatory diseases (IMIDs) is a term that encompasses a number of common, chronic and complex disorders, characterized by a dysregulation of the normal immune response which leads to inflammation in target organs and, usually, systemic effects as well.

Examples include type 1 diabetes (T1D), Crohn's disease (CD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS) and psoriasis. This report examines the therapeutic products and strategies that are being employed to improve outcomes by modulating the intracellular production of inflammatory mediators.

What You Will Learn

  • What are the immune factors in the Th17 helper cell pathway that are responsible for immune-mediated inflammatory Autoimmune Diseases?
  • What are the inflammatory-mediated ligands, receptors, signalling proteins and transcription factors that represent druggable targets in the Th17 helper cell?
  • What are the major factors driving the high level of development activity in immune-mediated inflammatory diseases?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2022?
  • What are the significant economic, technology, and regulatory factors affecting the market for immune therapeutics

Key Topics Covered:

  • Executive Summary
  • The Th17 Pathway

Th17 Inflammatory Pathway Cascade Targets

  • Interleukin 6 (IL-6)
  • Approved Drugs
  • Development-stage Drugs
  • Interleukin IL-6R
  • Approved Drugs
  • Development-stage Drugs

Janus Kinase/Tyrosine Kinase Inhibitors

  • Approved Drugs
  • Development-stage Drugs
  • Signalling Proteins

Signal Transducer and Activator of Transcription (STAT)

  • Interleukin-21 (IL-21)
  • Interleukin-21R (IL-21R)
  • Interleukin-23 (IL-23)
  • Approved Drugs
  • Development-stage Drugs
  • Interleukin-23R (IL-23R)
  • Interleukin-17A (IL-17A)
  • Approved Drugs
  • Interleukin-17C (IL-17C)
  • Development-stage Drugs
  • Interleukin 17A/17F
  • Development-stage Drugs
  • Interleukin-17RA (IL-17RA)
  • Approved Drugs

Transforming Growth Factor- RI/RII (TGF- RI/RII)

  • Development-stage Drugs
  • Retinoic acid-related orphan receptor (RORyt)
  • Development-stage Drugs
  • Interleukin 17
  • Development-stage Drugs
  • Interleukin-22 (IL-22)
  • Market Status
  • Market Size
  • Competitive Landscape

Th17 Pathway Mediated Inflammatory Diseases

  • Addressable Market
  • Competitive Landscape
  • Profiles of Market Participants

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets